Navigation Links
Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
Date:5/1/2013

LONDON, May 1, 2013 /PRNewswire/ -- The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market for Hepatitis B and C.

New analysis from Frost & Sullivan (http://www.lifesciences.frost.com), Analysis of European Hepatitis B and C Therapeutics Markets, finds that the Hepatitis B market earned revenues of $1.26 billion in 2012 and estimates this to reach $1.89 billion in 2019, while the Hepatitis C market is projected to expand from $2.40 billion to $3.66 billion over the same time period. The therapeutic segments covered include interferons and nucleoside analogues for Hepatitis B, and Standard of Care (Peginterferon alfa and Ribavirin) and protease inhibitors for Hepatitis C.

The side-effects associated with interferon-based therapeutics – such as fever, headache, fatigue, muscle and joint pain, shivering, and the ineffective response to Hepatitis C Virus (HCV) genotype 1 patients – are motivating the development of combination therapies.

"Improved drug efficiency, reduced pill burden and lower dosage frequency are among the common advantages related to the use of combination drugs," notes Frost & Sullivan Healthcare Research Analyst Deepika Pramod Chopda . "For instance, the combined use of interferon and interferon-free treatments is expected to yield positive results among infected patients; ribavirin-long acting interferons combination is estimated to boost the therapeutic success rate by over 50-60%."

The market is responding swiftly to the demand for improved therapeutic offerings. There has been an increase in new classes of compounds such as protease inhibitors
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
2. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
3. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
4. Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise
5. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
6. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
7. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
8. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
9. Scottsdale Healthcare, TGen study shows Abraxane/gemcitabine combination extends survival of pancreatic cancer patients
10. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
11. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
(Date:8/29/2014)... 2014 Pixcelldata, the innovative Irish ... announced a major new deal with Dutch based eX-Path, ... expert, Dr. Marius Nap . The ... Congress of Pathology which is taking placing between August ... London where Pixcelldata will demonstrate its ...
(Date:8/28/2014)... & Long, P.A.: , Do you, or did ... , Did you purchase your shares before September 10, ... , Did you lose money in your investment in ... your rights? Rigrodsky & Long, P.A. ... MacFall , announces that a complaint has been filed in the ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... Data Presented at ASCO -, CHICAGO, June ... Soliris(TM) (eculizumab), a new treatment for,paroxysmal nocturnal ... is effective in patients diagnosed with PNH,who ... or myelodysplastic,syndromes (MDS). Soliris significantly reduced red ...
... Onset and Total Sleep,Time, and Key Secondary Endpoints, ... Doses, HAMBURG, Germany and OXFORD, England, June 04, ... from its first phase II clinical trial of ... 201 is a partial,positive allosteric modulator (pPAM) of ...
Cached Medicine Technology:Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 2Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 3Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 4Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 5Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 6Soliris Effective in PNH Patients With History of Aplastic Anemia,and Myelodysplastic Syndromes 7Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201 2Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201 3Evotec Reports Positive Proof-of-Concept Top-Line Results with,Insomnia Drug Candidate EVT 201 4
(Date:8/30/2014)... 2014 After offering hyperbaric oxygen ... the past several years, Dr. Roy Schmidt and ... announced a scholarship program for veterans who have ... meeting held this summer to discuss veterans’ needs ... have shed light on the large number of ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Insomnia causes disturbances ... listeners understand how they unknowingly developed insomnia and the steps ... nights during. Tune in to the show at this ... show airs live on August 30, and will be podcasted ... on programming, go to DrCarolFrancisTalkRadio.com. , "Insomnia causes ...
(Date:8/30/2014)... 30, 2014 "My wife suffered neck, ... car accident," said one of two inventors from Bethel, ... her shoulder and neck area. She tried other pillows ... and pressure, assisting in comfort and providing extra sleep." ... CRADLE to support the head, neck and back comfortably. ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... company, Profit By Search announces the Labor Day ... the clients will surely get the complete services related ... as SEO professionals, Content Writers, and others do have ... to perfection that reflects in their work and since ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... and sleep apnea (a medical problem where the airway ... their bed partners of the rest they need to ... population snores and 20 million people in the United ... have been diagnosed and treated; and of those treated, ...
Breaking Medicine News(10 mins):Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... in Canadian hospitals, way beyond estimation, raising concern among ... investigator in the study said, “The stark reality in ... and other drug-resistant bacteria are posing a serious threat ... these super bugs are more likely to have longer ...
... a drug charity has revealed that young men are ... looks as well as to boost their self-confidence.// ... body builders and athletes to improve their performance, were ... building site workers between the ages 16 and 25. ...
... been developed by a researcher from Cornell University that detects ... in food processing.// , ‘It’s very inexpensive, it ... and it could be activated for whatever you want to ... Professor of Fibre Science and Apparel Design at Cornell. ...
... next week the distribution of a drug to help fight ... Africa is being affected by an extremely virulent strain of ... in the country. The health officials have now promised that ... next week to help fight the disease. The officials but ...
... properly for their safety and efficacy, says a ... // The drugs that are being indiscriminately prescribed ... ,The researchers analyzed drugs covered by a "congressionally ... the Food and Drug Administration (FDA) may extend ...
... branded inhalation capsules in India for the treatment of ... Beta2-agonist Formoterol and the most potent inhaled corticosteroid Fluticasone, ... 100 mcg, Avessa 250 mcg, Avessa 500 mcg, depending ... product is to be used only with the Rheohaler ...
Cached Medicine News:Health News:Nanotech Wipes for biohazard detection 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 2Health News:Doctors Unaware If Pediatric Dosages Are Safe 3
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
Contains 5 mg of penicillin, 5 mg of streptomycin, and 10 mg of neomycin/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and neomycin sulfate in 0.85% saline....
Medicine Products: